Targeted Therapies in Advanced Gastric Cancer

Timil H. Patel,Michael Cecchini

DOI: https://doi.org/10.1007/s11864-020-00774-4

2020-07-28

Current Treatment Options in Oncology

Abstract:Despite a decreasing incidence in the USA, gastric cancer is highly prevalent worldwide. Furthermore, gastric cancer remains highly lethal with median survival of less than 1 year for metastatic disease. The backbone of therapy against metastatic gastric cancer remains cytotoxic chemotherapy, but recent advances in the molecular understanding of gastric cancer have renewed hope within that targeted agents can be leveraged to improve survival and reduce toxicity. For example, in patients with human epidermal growth factor-2 (HER2)-positive gastric cancer, the addition of trastuzumab to frontline chemotherapy improves survival. In the second line, oncologists can now administer a vascular endothelial growth factor (VEGF) receptor inhibitor, ramucirumab, as a single agent or in combination with chemotherapy, and the immune checkpoint inhibitor pembrolizumab is approved in multiple settings dependent on the Programmed Death Ligand 1 (PD-L1) status. For patients with metastatic disease, our approach to standard of care in the first-line setting is a 5FU/platinum doublet with trastuzumab for HER2-positive tumors. In the second-line setting, most patients receive ramucirumab + paclitaxel, but those that are MSI high receive pembrolizumab. For squamous cell carcinoma of the esophagus with high PD-L1 status (combined positive score (CPS) ≥ 10), we recommend pembrolizumab in the second line. While for PD-L1 ≥ 1% gastroesophageal adenocarcinoma, we do not recommend pembrolizumab before the third-line setting, although this may change in the near future for CPS ≥ 10. The future landscape for targeted therapy in gastric cancer is promising. Numerous clinical trials evaluating the combination immune therapy with molecularly targeted agents are generating much excitement. Moreover, genomic data from The Cancer Center Genome (TCGA) and Asian Cancer Research Group (ACRG) classifications is being used to identify molecular subtypes to enable future clinical trials to include biomarker-enriched patient populations.

oncology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is how to improve the survival rate of patients and reduce the toxicity of treatment through targeted therapy in advanced gastric cancer. Specifically, the paper explores the following aspects:

1. **Targeted therapy for HER2 - positive gastric cancer**: The paper discusses multiple targeted drugs for HER2 - positive gastric cancer, such as Trastuzumab, Trastuzumab emtansine, Pertuzumab, Lapatinib, Trastuzumab deruxtecan and Margetuximab. Among them, Trastuzumab combined with chemotherapy significantly improved the median overall survival (mOS) of patients in first - line treatment, while other drugs such as Trastuzumab emtansine and Pertuzumab failed to show significant survival advantages in clinical trials.

2. **Use of VEGF inhibitors**: The paper evaluates the application of vascular endothelial growth factor (VEGF) inhibitors in gastric cancer, especially Bevacizumab and Ramucirumab. Ramucirumab has shown significant survival advantages in second - line treatment, especially when combined with paclitaxel.

3. **Application of immune checkpoint inhibitors**: The paper discusses in detail the role of immune checkpoint inhibitors in the treatment of gastric cancer, especially Nivolumab and Pembrolizumab. These drugs have shown significant efficacy in third - line or higher - line treatment, especially for patients with positive PD - L1 expression.

4. **Other targeted treatment strategies**: The paper also involves some other targeted treatment strategies, such as mTOR inhibitors (such as Everolimus), MET inhibitors (such as Rilotumumab and Onartuzumab) and PARP inhibitors (such as Olaparib). However, these drugs failed to show significant survival advantages in clinical trials.

Overall, this paper aims to provide clinicians with the latest treatment options and strategies by summarizing and analyzing the latest progress in the field of gastric cancer targeted therapy in recent years, in order to improve the prognosis of patients with advanced gastric cancer.